SEMA3F: A Novel Tumor-Suppressive Semaphorin Target Enabling Precision Research and Detection in Cancer Metastasis and Vascular Homeostasis
Dysregulated cell migration, pathological angiogenesis, and an imbalanced tumor microenvironment underlie tumor invasion and metastasis, chronic vascular disorders, and aberrant tissue proliferation. SEMA3F (Semaphorin 3F), a classical secreted axon guidance cue, stands out within the Semaphorin 3 family as a prototypical tumor suppressor and anti-angiogenic target. Unlike most family members that promote disease progression, SEMA3F exerts unique negative regulatory effects, precisely inhibiting tumor migration and invasion, blocking aberrant vascular proliferation, and remodeling the immune microenvironment. It has emerged as a promising biomarker for research into metastatic mechanisms, anti-angiogenic drug development, and vascular homeostasis disorders, offering new technical avenues for prognostic assessment and targeted mechanism studies.
Under physiological conditions, SEMA3F is expressed at low basal levels in lung, breast, colon, neural, and vascular endothelial tissues. It primarily participates in embryonic axon guidance, vascular morphogenesis, and the developmental patterning of tissues and organs, maintaining orderly cell migration and tissue homeostasis. Under pathological conditions, SEMA3F is frequently silenced or markedly downregulated through promoter methylation, chromosomal deletion, or aberrant transcriptional regulation. Loss of its inhibitory function releases constraints on tumor and endothelial cells, driving malignant progression and establishing SEMA3F as a classic tumor-suppressive target.
Vascular regulation. SEMA3F is a natural inhibitor of pathological angiogenesis. It specifically targets vascular endothelial cells, markedly suppressing their proliferation, migration, and tube formation while blocking VEGF-driven activation of pro-angiogenic signaling. This effectively inhibits tumor neovascularization, reduces nutrient supply to tumor lesions, and restrains tumor growth and invasion. It also suppresses pathological vascular remodeling such as ocular neovascularization and inflammatory vascular hyperplasia.
Tumor regulation. SEMA3F acts directly on tumor cells to inhibit epithelial-mesenchymal transition (EMT), reducing cell motility and invasive potential and thereby blocking local invasion and distant metastasis. When SEMA3F is silenced, the barrier restraining tumor cell migration collapses and invasive pathways remain constitutively active, substantially elevating the risk of malignant progression.
Immune regulation. SEMA3F modulates immune cell infiltration in the tumor microenvironment, inhibiting aberrant recruitment of tumor-associated macrophages (TAMs), alleviating local immunosuppression, and enhancing anti-tumor immune responses to break the tumor immune-evasion barrier. Together, these effects confer multi-dimensional tumor suppression across the vascular, cellular, and immune levels.
1. Malignant solid tumors: a biomarker of metastasis suppression and favorable prognosis
SEMA3F is broadly downregulated in common solid tumors, including non-small cell lung cancer, breast cancer, colorectal cancer, ovarian cancer, and gastric cancer. Large cohort studies consistently demonstrate that patients with low SEMA3F expression present at more advanced tumor stages, with significantly higher risks of lymph node and distant metastasis, higher postoperative recurrence rates, and poorer long-term outcomes. Its silencing is primarily driven by promoter methylation, an epigenetic mechanism. SEMA3F thus serves as a core biomarker for metastasis risk stratification, prognostic evaluation, and epigenetic mechanism research, as well as a potential therapeutic target for anti-metastatic and anti-angiogenic therapies.
2. Vascular proliferative disorders: a key regulator of vascular homeostasis
SEMA3F helps maintain systemic vascular homeostasis. Insufficient expression leads to dysregulated vascular proliferation, contributing to ocular neovascular diseases, hemangiomas, and chronic ischemic vascular remodeling. By suppressing aberrant endothelial proliferation and vascular remodeling, SEMA3F is both a target for mechanistic study and a candidate intervention point for vascular proliferative disorders, opening new directions for vascular homeostasis research.
3. Chronic inflammation and developmental disorders
SEMA3F is involved in neural development and inflammatory microenvironment regulation. Aberrant expression can disrupt axonal development and mediate imbalanced inflammatory cell infiltration, contributing to the onset and progression of chronic, persistent inflammation. It serves as an auxiliary target for inflammatory microenvironment regulation and for research into the mechanisms underlying developmental defects.
1. Gene-level detection
Quantitative PCR (qPCR), methylation sequencing, and next-generation sequencing (NGS) enable detection of SEMA3F mRNA transcript levels, promoter methylation status, and gene mutations or deletions. These methods are foundational for dissecting target silencing mechanisms, validating gene expression in cell models, and conducting tumor epigenetic research.
2. In situ tissue detection
Immunohistochemistry (IHC) and immunofluorescence (IF) enable in situ localization and semi-quantitative analysis of SEMA3F protein in tumor and vascular tissues, directly visualizing protein expression intensity and cellular distribution in lesions. They are ideal for tumor microenvironment analysis and phenotypic validation of vascular lesions.
3. Protein quantification
ELISA and Western blot serve as core quantitative technologies for precisely measuring SEMA3F protein levels in serum, plasma, cell culture supernatants, and tissue homogenates. Among these, ELISA, with its high throughput, convenience, and efficiency, has become the mainstream tool for large-cohort studies, drug efficacy evaluation, and between-group comparisons, supporting the full spectrum of SEMA3F research needs.
The product delivers four core advantages: high sensitivity, exceptional specificity, a broad linear range, and high stability and reproducibility, with performance on par with top-tier industry standards.
Sensitivity. Through in-depth system optimization, the kit achieves a detection limit of 19.25 pg/mL, enabling reliable detection of extremely low-abundance secreted SEMA3F in cell culture supernatants, micro-volume tissue homogenates, and serum samples. It eliminates missed detections, low-biased readings, and run-to-run variability in low-expression samples, supporting demanding research applications such as early, subtle tumor changes, mild vascular homeostasis disruption, and low-dose drug modulation.
Specificity. The kit employs SEMA3F-specific antibody pairs that precisely recognize unique epitopes, with minimal cross-reactivity to homologous Semaphorin family proteins and negligible background signal, eliminating non-specific interference from family members. The resulting measurements faithfully reflect true SEMA3F expression levels, providing accurate and reliable quantitative evidence for mechanistic research.
Broad linear range. The kit covers a wide linear range of 46.8–3,000 pg/mL, accommodating both low physiological baseline levels and pathologically elevated expression. This substantially reduces serial dilution steps, minimizing manual dilution error at the source and delivering reproducibility and data stability that exceed common industry standards. The product is compatible with human and model-organism samples across serum, plasma, tissue homogenates, cell lysates, and cell culture supernatants. The assay is easy to perform, requires no specialized high-end instrumentation, and runs in standard molecular biology laboratories, efficiently supporting tumor metastasis research, anti-angiogenic drug efficacy evaluation, epigenetic target validation, and large-scale clinical cohort studies.
I. Basic Profile of SEMA3F: A Highly Conserved Tumor-Suppressive Semaphorin Gene
SEMA3F is a key functional gene located on human chromosome 3p21.3, a region that is frequently deleted or mutated across human cancers yet evolutionarily conserved. The gene encodes a secreted glycoprotein whose mature form is released directly into the extracellular matrix. As a soluble extracellular signaling molecule, it acts at a distance on neighboring cells without requiring intracellular activation, a distinct advantage over intracellular transcription factors.Under physiological conditions, SEMA3F is expressed at low basal levels in lung, breast, colon, neural, and vascular endothelial tissues. It primarily participates in embryonic axon guidance, vascular morphogenesis, and the developmental patterning of tissues and organs, maintaining orderly cell migration and tissue homeostasis. Under pathological conditions, SEMA3F is frequently silenced or markedly downregulated through promoter methylation, chromosomal deletion, or aberrant transcriptional regulation. Loss of its inhibitory function releases constraints on tumor and endothelial cells, driving malignant progression and establishing SEMA3F as a classic tumor-suppressive target.
II. Mechanism of Action: Tripartite Regulation Suppressing Tumor Progression and Aberrant Vascular Proliferation
SEMA3F initiates downstream signaling by binding to the cell-surface Neuropilin-2/Plexin-A receptor complex, exerting negative regulation along three axes: inhibiting angiogenesis, blocking metastasis, and remodeling the immune microenvironment. It serves as a key endogenous safeguard against tumor invasion and vascular dysregulation.Vascular regulation. SEMA3F is a natural inhibitor of pathological angiogenesis. It specifically targets vascular endothelial cells, markedly suppressing their proliferation, migration, and tube formation while blocking VEGF-driven activation of pro-angiogenic signaling. This effectively inhibits tumor neovascularization, reduces nutrient supply to tumor lesions, and restrains tumor growth and invasion. It also suppresses pathological vascular remodeling such as ocular neovascularization and inflammatory vascular hyperplasia.
Tumor regulation. SEMA3F acts directly on tumor cells to inhibit epithelial-mesenchymal transition (EMT), reducing cell motility and invasive potential and thereby blocking local invasion and distant metastasis. When SEMA3F is silenced, the barrier restraining tumor cell migration collapses and invasive pathways remain constitutively active, substantially elevating the risk of malignant progression.
Immune regulation. SEMA3F modulates immune cell infiltration in the tumor microenvironment, inhibiting aberrant recruitment of tumor-associated macrophages (TAMs), alleviating local immunosuppression, and enhancing anti-tumor immune responses to break the tumor immune-evasion barrier. Together, these effects confer multi-dimensional tumor suppression across the vascular, cellular, and immune levels.
III. Disease Association: A Core Biomarker for Cancer, Vascular Disorders, and Inflammatory Diseases
Downregulated expression and functional inactivation of SEMA3F contribute to malignant progression in multiple solid tumors, vascular homeostasis disruption, and chronic inflammation. Its expression correlates inversely with disease stage and metastatic risk and is predictive of prognostic grade, making SEMA3F a highly valuable research target for disease assessment.1. Malignant solid tumors: a biomarker of metastasis suppression and favorable prognosis
SEMA3F is broadly downregulated in common solid tumors, including non-small cell lung cancer, breast cancer, colorectal cancer, ovarian cancer, and gastric cancer. Large cohort studies consistently demonstrate that patients with low SEMA3F expression present at more advanced tumor stages, with significantly higher risks of lymph node and distant metastasis, higher postoperative recurrence rates, and poorer long-term outcomes. Its silencing is primarily driven by promoter methylation, an epigenetic mechanism. SEMA3F thus serves as a core biomarker for metastasis risk stratification, prognostic evaluation, and epigenetic mechanism research, as well as a potential therapeutic target for anti-metastatic and anti-angiogenic therapies.
2. Vascular proliferative disorders: a key regulator of vascular homeostasis
SEMA3F helps maintain systemic vascular homeostasis. Insufficient expression leads to dysregulated vascular proliferation, contributing to ocular neovascular diseases, hemangiomas, and chronic ischemic vascular remodeling. By suppressing aberrant endothelial proliferation and vascular remodeling, SEMA3F is both a target for mechanistic study and a candidate intervention point for vascular proliferative disorders, opening new directions for vascular homeostasis research.
3. Chronic inflammation and developmental disorders
SEMA3F is involved in neural development and inflammatory microenvironment regulation. Aberrant expression can disrupt axonal development and mediate imbalanced inflammatory cell infiltration, contributing to the onset and progression of chronic, persistent inflammation. It serves as an auxiliary target for inflammatory microenvironment regulation and for research into the mechanisms underlying developmental defects.
IV. Detection Technologies: A Multi-Dimensional, Integrated Platform for Research Applications
As research on SEMA3F has advanced, a mature three-pronged technology system has been established, spanning gene expression and methylation detection, protein quantification, and in situ tissue detection. It enables multi-dimensional analysis of SEMA3F status at the genetic/epigenetic, protein-expression, and tissue-localization levels for a wide range of research applications.1. Gene-level detection
Quantitative PCR (qPCR), methylation sequencing, and next-generation sequencing (NGS) enable detection of SEMA3F mRNA transcript levels, promoter methylation status, and gene mutations or deletions. These methods are foundational for dissecting target silencing mechanisms, validating gene expression in cell models, and conducting tumor epigenetic research.
2. In situ tissue detection
Immunohistochemistry (IHC) and immunofluorescence (IF) enable in situ localization and semi-quantitative analysis of SEMA3F protein in tumor and vascular tissues, directly visualizing protein expression intensity and cellular distribution in lesions. They are ideal for tumor microenvironment analysis and phenotypic validation of vascular lesions.
3. Protein quantification
ELISA and Western blot serve as core quantitative technologies for precisely measuring SEMA3F protein levels in serum, plasma, cell culture supernatants, and tissue homogenates. Among these, ELISA, with its high throughput, convenience, and efficiency, has become the mainstream tool for large-cohort studies, drug efficacy evaluation, and between-group comparisons, supporting the full spectrum of SEMA3F research needs.
V. In-House SEMA3F ELISA Product: A High-Sensitivity, High-Specificity Precision Research Solution
Conventional SEMA3F detection kits on the market face persistent industry challenges: high sequence homology among Semaphorin family proteins causes frequent non-specific cross-reactivity and elevated background noise; insufficient sensitivity makes it difficult to reliably detect low-abundance secreted SEMA3F in vivo, leading to frequent false negatives; and narrow linear ranges accommodate neither high- nor low-concentration samples, forcing serial dilutions that introduce experimental error and poor reproducibility. These shortcomings severely limit fine-grained mechanistic studies and high-throughput sample testing. Addressing these limitations, we have independently developed Human Semaphorin 3F (SEMA3F) ELISA Kit leveraging mature, precise antigen-antibody pairing technology and optimized solid-phase coating chemistry. Designed specifically for tumor metastasis research, vascular homeostasis studies, drug screening, and clinical-sample research, it overcomes the long-standing bottlenecks of conventional assays.The product delivers four core advantages: high sensitivity, exceptional specificity, a broad linear range, and high stability and reproducibility, with performance on par with top-tier industry standards.
Sensitivity. Through in-depth system optimization, the kit achieves a detection limit of 19.25 pg/mL, enabling reliable detection of extremely low-abundance secreted SEMA3F in cell culture supernatants, micro-volume tissue homogenates, and serum samples. It eliminates missed detections, low-biased readings, and run-to-run variability in low-expression samples, supporting demanding research applications such as early, subtle tumor changes, mild vascular homeostasis disruption, and low-dose drug modulation.
Specificity. The kit employs SEMA3F-specific antibody pairs that precisely recognize unique epitopes, with minimal cross-reactivity to homologous Semaphorin family proteins and negligible background signal, eliminating non-specific interference from family members. The resulting measurements faithfully reflect true SEMA3F expression levels, providing accurate and reliable quantitative evidence for mechanistic research.
Broad linear range. The kit covers a wide linear range of 46.8–3,000 pg/mL, accommodating both low physiological baseline levels and pathologically elevated expression. This substantially reduces serial dilution steps, minimizing manual dilution error at the source and delivering reproducibility and data stability that exceed common industry standards. The product is compatible with human and model-organism samples across serum, plasma, tissue homogenates, cell lysates, and cell culture supernatants. The assay is easy to perform, requires no specialized high-end instrumentation, and runs in standard molecular biology laboratories, efficiently supporting tumor metastasis research, anti-angiogenic drug efficacy evaluation, epigenetic target validation, and large-scale clinical cohort studies.
